aTyr Pharma Receives FDA Fast Track Designation for Efzofitimod for Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
Second Fast Track designation for efzofitimod clinical program. Efzofitimod previously received FDA orphan drug designation…